{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:09:00Z","timestamp":1779361740150,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study evaluates the changing burden of hepatitis C (HCV) among women of reproductive age (15\u201349\u00a0years) in China from 1990\u20132021 and forecasts trends to 2035.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from the Global Burden of Disease 2021 study, we analyzed age-standardized rates (ASRs) for incidence, prevalence, mortality, and disability-adjusted life years (DALYs) related to acute and chronic HCV in this population. Statistical analyses included estimating annual percentage changes (EAPCs), applying Poisson-based age-period-cohort (APC) modeling to assess epidemiological drivers, and employing Bayesian APC modeling for future projections. Decomposition analysis was used to quantify contributions from population growth, aging, and epidemiological factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 1990 to 2021, all ASRs for HCV among women of reproductive age in China showed significant declines, with rates of decrease surpassing global averages. Despite this progress, China remained a high-burden country for this group in 2021, with a large reservoir of chronic HCV cases. A notable rebound in the incidence of chronic HCV occurred after 2010. Epidemiological trends displayed clear age stratification: the most substantial improvements were observed in younger cohorts (aged 15\u201324\u00a0years), while older groups (aged 45\u201349\u00a0years) experienced slower declines or recent rebounds in incidence. Decomposition analysis indicated that the reduction in disease burden was primarily driven by epidemiological improvements (e.g., in prevention and treatment), which successfully offset the adverse effects of population growth. This pattern contrasts with the global trend, where increasing burden is largely attributed to demographic factors. Projections suggest a continued decline in ASRs and case numbers through 2035, although the rate of decline is expected to slow.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Historical HCV control measures for women of reproductive age in China have been effective, as evidenced by steep declines in mortality and DALYs. However, persistent challenges include a substantial existing patient pool and a resurgent incidence, particularly among older individuals within this demographic. This study precisely quantifies a successful epidemiological transition and identifies a shift in risk profiles, underscoring the continued need for sustained, age-tailored public health interventions to achieve HCV elimination goals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-026-03079-4","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:02:09Z","timestamp":1779357729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The three-decade trajectory of hepatitis C burden among women of reproductive age in China: a retrospective and predictive study"],"prefix":"10.1186","volume":"23","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"25","key":"3079_CR1","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","volume":"364","author":"HR Rosen","year":"2011","unstructured":"Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429\u201338.","journal-title":"N Engl J Med"},{"issue":"8","key":"3079_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","volume":"19","author":"MP Manns","year":"2022","unstructured":"Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022;19(8):533\u201350.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3079_CR3","unstructured":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5): 396\u2013415."},{"issue":"4","key":"3079_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1055\/s-0031-1297922","volume":"31","author":"J Grebely","year":"2011","unstructured":"Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31(4):331\u20139.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"3079_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s43657-023-00136-8","volume":"3","author":"J Wu","year":"2023","unstructured":"Wu J, Liu W, Qiu X, et al. A noninvasive approach to evaluate tumor immune microenvironment and predict outcomes in hepatocellular carcinoma. Phenomics. 2023;3(6):549\u201364.","journal-title":"Phenomics"},{"issue":"Suppl 1","key":"3079_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1478-3231.2008.01928.x","volume":"29","author":"T Asselah","year":"2009","unstructured":"Asselah T, Benhamou Y, Marcellin P. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int. 2009;29(Suppl 1):57\u201367.","journal-title":"Liver Int"},{"issue":"6","key":"3079_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2893.2009.01124.x","volume":"16","author":"AJ Thompson","year":"2009","unstructured":"Thompson AJ, Mchutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat. 2009;16(6):377\u201387.","journal-title":"J Viral Hepat"},{"issue":"12","key":"3079_CR8","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1111\/liv.15452","volume":"42","author":"G Ouyang","year":"2022","unstructured":"Ouyang G, Pan G, Guan L, et al. Incidence trends of acute viral hepatitis caused by four viral etiologies between 1990 and 2019 at the global, regional and national levels. Liver Int. 2022;42(12):2662\u201373.","journal-title":"Liver Int"},{"issue":"2","key":"3079_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhepr.2019.04.002","volume":"1","author":"S Smith","year":"2019","unstructured":"Smith S, Harmanci H, Hutin Y, et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO member state responses 2017. JHEP Rep. 2019;1(2):81\u20139.","journal-title":"JHEP Rep"},{"issue":"2","key":"3079_CR10","doi-asserted-by":"publisher","first-page":"e25050","DOI":"10.1002\/jia2.25050","volume":"21","author":"YJ Hutin","year":"2018","unstructured":"Hutin YJ, Bulterys M, Hirnschall GO. How far are we from viral hepatitis elimination service coverage targets? J Int AIDS Soc. 2018;21(2):e25050.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"3079_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2055-6640(20)30264-8","volume":"4","author":"S Popping","year":"2018","unstructured":"Popping S, El-Sayed M, Feld J, et al. Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework. J Virus Erad. 2018;4(3):193\u20135.","journal-title":"J Virus Erad"},{"issue":"2","key":"3079_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000026","volume":"7","author":"Y Lan","year":"2023","unstructured":"Lan Y, Wang H, Weng H, et al. The burden of liver cirrhosis and underlying etiologies: results from the Global Burden of Disease Study 2019. Hepatol Commun. 2023;7(2):e0026.","journal-title":"Hepatol Commun"},{"issue":"3","key":"3079_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3350\/cmh.2022.0349","volume":"29","author":"CH Liu","year":"2023","unstructured":"Liu CH, Kao JH. Acute hepatitis C virus infection: clinical update and remaining challenges. Clin Mol Hepatol. 2023;29(3):623\u201342.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"3079_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1590-8658(03)00007-0","volume":"35","author":"T Santantonio","year":"2003","unstructured":"Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003;35(2):104\u201313.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"3079_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12985-025-02869-6","volume":"22","author":"Z Ying","year":"2025","unstructured":"Ying Z, Jing Y, Tong W, Chaoyan Y. Spatiotemporal evolution of HCV burden among women of reproductive age: a multinational age-period-cohort analysis. Virol J. 2025;22(1):265.","journal-title":"Virol J"},{"key":"3079_CR16","unstructured":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England), 2020; 396(10258): 1204\u201322."},{"issue":"10204","key":"3079_CR17","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145\u201358.","journal-title":"Lancet"},{"issue":"12","key":"3079_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296053","volume":"18","author":"J Ye","year":"2023","unstructured":"Ye J, Sun Y, Li J, et al. Distribution pattern, molecular transmission networks, and phylodynamic of hepatitis C virus in China. PLoS ONE. 2023;18(12):e0296053.","journal-title":"PLoS ONE"},{"issue":"13","key":"3079_CR19","first-page":"435","volume":"7","author":"H Jiang","year":"2025","unstructured":"Jiang H, Liang S, Wu X, et al. Using Phylogenetic Analysis to Detect National and International Dimensions of Hepatitis C Virus 1b Transmission Clusters - China, 1989\u20132021. China CDC Weekly. 2025;7(13):435\u201340.","journal-title":"China CDC Weekly"},{"key":"3079_CR20","unstructured":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(3): 161\u201376."},{"issue":"3","key":"3079_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz040","volume":"6","author":"Y Gao","year":"2019","unstructured":"Gao Y, Yang J, Sun F, et al. Prevalence of anti-HCV antibody among the general population in Mainland China between 1991 and 2015: a systematic review and meta-analysis. Open Forum Infect Dis. 2019;6(3):ofz040.","journal-title":"Open Forum Infect Dis"},{"key":"3079_CR22","doi-asserted-by":"crossref","unstructured":"BAI J, LV H, WANG L, et al. Global, regional, and National burden of hepatitis C from 1990 to 2021 and projections until 2030. BMC Infect Dis. 2025.","DOI":"10.1186\/s12879-025-12396-y"},{"issue":"10","key":"3079_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14787210.2019.1675509","volume":"17","author":"M Li","year":"2019","unstructured":"Li M, Zhuang H, Wei L. How would China achieve WHO\u2019s target of eliminating HCV by 2030? Expert Rev Anti-Infect Ther. 2019;17(10):763\u201373.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"3079_CR24","doi-asserted-by":"crossref","unstructured":"MUGGEO V M. Comment on 'Estimating average annual per cent change in trend analysis' by Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK, Statistics in Medicine 2009; 28:3670-3682. Statistics Med. 2010, 29(18): 1958\u201360; author reply 61.","DOI":"10.1002\/sim.3850"},{"issue":"29","key":"3079_CR25","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/sim.3733","volume":"28","author":"LX Clegg","year":"2009","unstructured":"Clegg LX, Hankey BF, Tiwari R, et al. Estimating average annual per cent change in trend analysis. Stat Med. 2009;28(29):3670\u201382.","journal-title":"Stat Med"},{"issue":"10","key":"3079_CR26","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1161\/CIRCULATIONAHA.119.042864","volume":"141","author":"Z Zou","year":"2020","unstructured":"Zou Z, Cini K, Dong B, et al. Time trends in cardiovascular disease mortality across the BRICS: an age-period-cohort analysis of key nations with emerging economies using the Global Burden of Disease Study 2017. Circulation. 2020;141(10):790\u20139.","journal-title":"Circulation"},{"issue":"3","key":"3079_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/bimj.201500263","volume":"59","author":"A Riebler","year":"2017","unstructured":"Riebler A, Held L. Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations. Biometr J Biometrische Zeitschrift. 2017;59(3):531\u201349.","journal-title":"Biometr J Biometrische Zeitschrift"},{"key":"3079_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijid.2018.11.006","volume":"80","author":"CR Liu","year":"2019","unstructured":"Liu CR, Li X, Chan PL, et al. Prevalence of hepatitis C virus infection among key populations in China: A systematic review. Int J Infect Dis. 2019;80:16\u201327.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"3079_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106298","volume":"89","author":"B Wen","year":"2024","unstructured":"Wen B, Te L, Bai C, et al. Relative contribution of hepatitis B and C viruses in primary liver cancer in China: a systematic review and meta-analysis. J Infect. 2024;89(6):106298.","journal-title":"J Infect"},{"issue":"8","key":"3079_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/MCG.0000000000000109","volume":"48","author":"Z Duan","year":"2014","unstructured":"Duan Z, Jia JD, Hou J, et al. Current challenges and the management of chronic hepatitis C in mainland China. J Clin Gastroenterol. 2014;48(8):679\u201386.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3079_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40249-023-01081-4","volume":"12","author":"X Du","year":"2023","unstructured":"Du X, Mi J, Cheng H, et al. Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021. Infect Dis Poverty. 2023;12(1):28.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"3079_CR32","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12876-023-03016-7","volume":"23","author":"L Zheng","year":"2023","unstructured":"Zheng L, Zhang X, Nian Y, et al. Multi-disciplinary cooperation for the micro-elimination of hepatitis C in China: a hospital-based experience. BMC Gastroenterol. 2023;23(1):386.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"3079_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(20)30359-9","volume":"6","author":"E Dugan","year":"2021","unstructured":"Dugan E, Blach S, Biondi M, et al. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. Lancet Gastroenterol Hepatol. 2021;6(3):169\u201384.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3079_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2464931","volume":"57","author":"S Chen","year":"2025","unstructured":"Chen S, Xu Y, Li B, et al. Pathway to hepatitis C elimination: insights from a large tertiary hospital in South China. Ann Med. 2025;57(1):2464931.","journal-title":"Ann Med"},{"issue":"3","key":"3079_CR35","first-page":"464","volume":"45","author":"PC Liu","year":"2024","unstructured":"Liu PC, Xu D, Ding GW, et al. Cost-effectiveness of HCV testing strategies for hepatitis C elimination in general population in China. Zhonghua liu xing bing xue za zhi Zhonghua liuxingbingxue zazhi. 2024;45(3):464\u201372.","journal-title":"Zhonghua liu xing bing xue za zhi Zhonghua liuxingbingxue zazhi"},{"issue":"10","key":"3079_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110861","volume":"9","author":"L Wang","year":"2014","unstructured":"Wang L, Xing J, Chen F, et al. Spatial analysis on hepatitis C virus infection in mainland China: from 2005 to 2011. PLoS ONE. 2014;9(10):e110861.","journal-title":"PLoS ONE"},{"issue":"12","key":"3079_CR37","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1002\/jmv.25745","volume":"92","author":"S Mushtaq","year":"2020","unstructured":"Mushtaq S, Mansoor A, Umar M, et al. Direct-acting antiviral agents in the treatment of chronic hepatitis C-real-life experience from clinical practices in Pakistan. J Med Virol. 2020;92(12):3475\u201387.","journal-title":"J Med Virol"},{"issue":"10 Pt 2","key":"3079_CR38","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1111\/trf.12297","volume":"53","author":"J Wang","year":"2013","unstructured":"Wang J, Liu J, Huang Y, et al. The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations. Transfusion. 2013;53(10 Pt 2):2489\u201397.","journal-title":"Transfusion"},{"issue":"3","key":"3079_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1586\/eri.09.8","volume":"7","author":"R Ozaras","year":"2009","unstructured":"Ozaras R, Tahan V. Acute hepatitis C: prevention and treatment. Expert Rev Anti-Infect Ther. 2009;7(3):351\u201361.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"7","key":"3079_CR40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/jvh.12677","volume":"24","author":"S Zhou","year":"2017","unstructured":"Zhou S, Cella E, Zhou W, et al. Population dynamics of hepatitis C virus subtypes in injecting drug users on methadone maintenance treatment in China associated with economic and health reform. J Viral Hepatitis. 2017;24(7):551\u201360.","journal-title":"J Viral Hepatitis"},{"key":"3079_CR41","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ijid.2022.06.017","volume":"122","author":"T Yue","year":"2022","unstructured":"Yue T, Zhang Q, Cai T, et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019. Int J Infect Dis. 2022;122:476\u201385.","journal-title":"Int J Infect Dis"},{"key":"3079_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1115087","volume":"13","author":"J Qian","year":"2023","unstructured":"Qian J, Yue M, Huang P, et al. Spatiotemporal heterogeneity and impact factors of hepatitis B and C in China from 2010 to 2018: bayesian space-time hierarchy model. Front Cell Infect Microbiol. 2023;13:1115087.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"3079_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10881-y","volume":"25","author":"G Tian","year":"2025","unstructured":"Tian G, Zheng Y, He Y, et al. Epidemiological trends of hepatitis C incidence and death in Mainland China between 2004 and 2018 and its predictions to 2030. BMC Infect Dis. 2025;25(1):483.","journal-title":"BMC Infect Dis"},{"issue":"24","key":"3079_CR44","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-5676","volume":"10","author":"M Yan","year":"2022","unstructured":"Yan M, Wu B. Hepatitis B and C mortality from 1990 to 2019 in China: a bayesian age-period-cohort analysis. Ann Transl Med. 2022;10(24):1384.","journal-title":"Ann Transl Med"},{"issue":"5","key":"3079_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4254\/wjh.v11.i5.421","volume":"11","author":"Q Xie","year":"2019","unstructured":"Xie Q, Xuan JW, Tang H, et al. Hepatitis C virus cure with direct acting antivirals: clinical, economic, societal and patient value for China. World J Hepatol. 2019;11(5):421\u201341.","journal-title":"World J Hepatol"},{"issue":"1","key":"3079_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2328521","volume":"56","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang M, Liu C, et al. Global burden of liver cirrhosis 1990-2019 and 20 years forecast: results from the global burden of disease study 2019. Ann Med. 2024;56(1):2328521.","journal-title":"Ann Med"},{"key":"3079_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.550205","volume":"11","author":"S Mushtaq","year":"2020","unstructured":"Mushtaq S, Akhter TS, Khan A, et al. Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir\/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan. Front Pharmacol. 2020;11:550205.","journal-title":"Front Pharmacol"},{"key":"3079_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.894460","volume":"13","author":"S Mushtaq","year":"2022","unstructured":"Mushtaq S, Hashmi AH, Khan A, et al. Emergence and persistence of resistance-associated substitutions in HCV GT3 patients failing direct-acting antivirals. Front Pharmacol. 2022;13:894460.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3079_CR49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11938-019-00240-7","volume":"17","author":"RK Dhiman","year":"2019","unstructured":"Dhiman RK, Grover GS, Premkumar M. Hepatitis C elimination: a public health perspective. Curr Treat Options Gastroenterol. 2019;17(3):367\u201377.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"12","key":"3079_CR50","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40273-024-01424-5","volume":"42","author":"M Wu","year":"2024","unstructured":"Wu M, Ma J, Li S, et al. Effects and costs of hepatitis C virus elimination for the whole population in China: a modelling study. Pharmacoeconomics. 2024;42(12):1345\u201357.","journal-title":"Pharmacoeconomics"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03079-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03079-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03079-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:02:23Z","timestamp":1779361343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03079-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3079"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03079-4","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study did not need approval because it used publicly available data. This study follows the Guidelines for Accurate and Transparent Health Estimates Reporting Guidelines for cross-sectional studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}